219 related articles for article (PubMed ID: 19117535)
1. Peptides presented in vivo by HLA-DR in thyroid autoimmunity.
Muixí L; Alvarez I; Jaraquemada D
Adv Immunol; 2008; 99():165-209. PubMed ID: 19117535
[TBL] [Abstract][Full Text] [Related]
2. Thyroglobulin peptides associate in vivo to HLA-DR in autoimmune thyroid glands.
Muixí L; Carrascal M; Alvarez I; Daura X; Martí M; Armengol MP; Pinilla C; Abian J; Pujol-Borrell R; Jaraquemada D
J Immunol; 2008 Jul; 181(1):795-807. PubMed ID: 18566446
[TBL] [Abstract][Full Text] [Related]
3. Inappropriate major histocompatibility complex class II expression by thyroid follicular cells in thyroid autoimmune disease and by pancreatic beta cells in type I diabetes.
Pujol-Borrell R; Todd I; Londei M; Foulis A; Feldmann M; Bottazzo GF
Mol Biol Med; 1986 Apr; 3(2):159-65. PubMed ID: 3090400
[TBL] [Abstract][Full Text] [Related]
4. Hyperinducibility of HLA class II expression of thyroid follicular cells from Graves' disease. A primary defect?
Sospedra M; Obiols G; Babi LF; Tolosa E; Vargas F; Roura-Mir C; Lucas-Martin A; Ercilla G; Pujol-Borrell R
J Immunol; 1995 Apr; 154(8):4213-22. PubMed ID: 7706756
[TBL] [Abstract][Full Text] [Related]
5. Intrathyroidal MHC class II antigen expression and thyroid autoimmunity.
Davies TF; Piccinini LA
Endocrinol Metab Clin North Am; 1987 Jun; 16(2):247-68. PubMed ID: 3319584
[TBL] [Abstract][Full Text] [Related]
6. Class II major histocompatibility complex and organ specific autoimmunity in man.
Foulis AK
J Pathol; 1986 Sep; 150(1):5-11. PubMed ID: 2946837
[TBL] [Abstract][Full Text] [Related]
7. Expression of adhesion molecules on infiltrating T cells in thyroid glands from patients with Graves' disease.
Ishikawa N; Eguchi K; Ueki Y; Nakashima M; Shimada H; Ito K; Nagataki S
Clin Exp Immunol; 1993 Nov; 94(2):363-70. PubMed ID: 7900942
[TBL] [Abstract][Full Text] [Related]
8. HLA-DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules.
Catálfamo M; Serradell L; Roura-Mir C; Kolkowski E; Sospedra M; Vives-Pi M; Vargas-Nieto F; Pujol-Borrell R; Jaraquemada D
Int Immunol; 1999 Feb; 11(2):269-77. PubMed ID: 10069425
[TBL] [Abstract][Full Text] [Related]
9. Expression of IFNalpha-inducible genes and modulation of HLA-DR and thyroid stimulating hormone receptors in Graves' disease.
Kuang M; Wang S; Wu M; Ning G; Yao Z; Li L
Mol Cell Endocrinol; 2010 May; 319(1-2):23-9. PubMed ID: 20015465
[TBL] [Abstract][Full Text] [Related]
10. Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes.
Li CW; Osman R; Menconi F; Concepcion ES; Tomer Y
J Autoimmun; 2017 Jan; 76():1-9. PubMed ID: 27670087
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance for autoimmunity.
Hanafusa T; Pujol-Borrell R; Chiovato L; Russell RC; Doniach D; Bottazzo GF
Lancet; 1983 Nov; 2(8359):1111-5. PubMed ID: 6138646
[TBL] [Abstract][Full Text] [Related]
12. Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves' disease.
Zantut-Wittmann DE; Tambascia MA; da Silva Trevisan MA; Pinto GA; Vassallo J
Thyroid; 2001 Jun; 11(6):575-80. PubMed ID: 11442005
[TBL] [Abstract][Full Text] [Related]
13. Extraordinary cross-reactivity of an autoimmune T-cell receptor recognizing specific peptides both on autologous and on allogeneic HLA class II molecules.
Hansen BE; Rasmussen AH; Jakobsen BK; Ryder LP; Svejgaard A
Tissue Antigens; 2007 Jul; 70(1):42-52. PubMed ID: 17559580
[TBL] [Abstract][Full Text] [Related]
14. Localization of HLA-DR alpha-chain messenger ribonucleic acid in normal and autoimmune human thyroid using in situ hybridization.
Piccinini LA; Goldsmith NK; Schachter BS; Davies TF
J Clin Endocrinol Metab; 1988 Jun; 66(6):1307-15. PubMed ID: 2453529
[TBL] [Abstract][Full Text] [Related]
15. Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules.
Falcioni F; Ito K; Vidovic D; Belunis C; Campbell R; Berthel SJ; Bolin DR; Gillespie PB; Huby N; Olson GL; Sarabu R; Guenot J; Madison V; Hammer J; Sinigaglia F; Steinmetz M; Nagy ZA
Nat Biotechnol; 1999 Jun; 17(6):562-7. PubMed ID: 10385320
[TBL] [Abstract][Full Text] [Related]
16. Pathogenetic relevance of HLA class II expressing thyroid follicular cells in nontoxic Goiter and in Graves' disease.
Grubeck-Loebenstein B; Londei M; Greenall C; Pirich K; Kassal H; Waldhäusl W; Feldmann M
J Clin Invest; 1988 May; 81(5):1608-14. PubMed ID: 3130398
[TBL] [Abstract][Full Text] [Related]
17. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
Neumann J; König A; Koch N
Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
[TBL] [Abstract][Full Text] [Related]
18. Characterization of HLA-DR-restricted T-cell epitopes derived from human proteinase 3.
Piesche M; Hildebrandt Y; Chapuy B; Wulf GG; Trümper L; Schroers R
Vaccine; 2009 Jul; 27(34):4718-23. PubMed ID: 19446593
[TBL] [Abstract][Full Text] [Related]
19. HLA class II transgenic mice mimic human inflammatory diseases.
Mangalam AK; Rajagopalan G; Taneja V; David CS
Adv Immunol; 2008; 97():65-147. PubMed ID: 18501769
[TBL] [Abstract][Full Text] [Related]
20. [Effect of insulin-like growth factor I on HLA-DR antigen expression in cultured human thyrocytes: a component of the autoimmune process?].
Aguayo J; Wohlik N; Pérez MV; Pineda G
Rev Med Chil; 1994 Mar; 122(3):248-52. PubMed ID: 7809513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
